A prominent gastrointestinal molecular diagnostics company, Cyted Health, has revealed on April 16, 2026, that they are currently conducting a clinical validation study at various locations in the United States. The company, headquartered in WILMINGTON, Del., and CAMBRIDGE, England, shared that their laboratory in the US has successfully accomplished this milestone. The study spans across multiple sites and is aimed at validating their technology and methods. This news signifies a significant step for Cyted Health as they work towards further establishing their presence in the field.